Nanozyme eye drops for retinal barrier penetration and vasculopathy repair
Science Advances · 19.09.2025 · 11 (38)
DOI: 10.1126/sciadv.adu5571 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, erschienen am 19.09.2025. Verfasst von Bai Xue und 10 weiteren Autor:innen. Beteiligte Einrichtung: Nanozyme Laboratory in Zhongyuan, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou 450001, China. Hauptthemen laut MEDLINE: Ophthalmic Solutions, Retinal Neovascularization, Blood-Retinal Barrier. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Retinal neovascularization diseases cause vision impairment due to abnormal blood vessel growth in the retina. Current treatments, including repeated intraocular anti–vascular endothelial growth factor injections, are invasive and often lead to discomfort and complicated hemorrhages. Here, we developed a noninvasive nanozyme eye drop capable of penetrating the fundus to eliminate reactive oxygen species (ROS) and thereby inhibit neovascularization. The nanozyme eye drops consist of liposomes formed by fluorinated and arginine–glycine–aspartic acid–modified phospholipids, which enhance the penetration of ocular barriers. The encapsulated superoxide dismutase–catalase cascade nanozyme within these liposomes allows for efficient ROS scavenging. In vitro and in vivo studies demonstrate that these nanozyme eye drops achieve deep retinal tissue penetration, alleviate oxidative stress, restore mitochondrial function, and suppress aberrant insulin-like growth factor binding protein 6 signaling, thereby inhibiting pathological neovascularization. Enhanced ocular bioavailability and minimal toxicity further underscore its promise as a safe and effective noninvasive treatment for retinal neovascularization diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Nanozyme Laboratory in Zhongyuan, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou 450001, China.
- Nanozyme Laboratory in Zhongyuan, Henan Academy of Innovations in Medical Science, Zhengzhou, Henan 451163, China.
- State Key Laboratory of Metabolic Dysregulation & Prevention and Treatment of Esophageal Cancer, Tianjian Laboratory of Advanced Biomedical Sciences, Academy of Medical Sciences, Zhengzhou University, Zhengzhou, Henan,…
- College of Chemistry and Materials, Jiangxi Normal University, Nanchang 330022, China.
- CAS Engineering Laboratory for Nanozyme, Key Laboratory of Biomacromolecules (CAS), CAS Center for Excellence in Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China.
- National Health Commission Cardiovascular Disease Regenerative Medicine Research Key Laboratory, Central China Subcenter of National Center for Cardiovascular Diseases, Henan Cardiovascular Disease Center, Fuwai Central…
ORCID-Profile: Bai Xue, Shuyu Wang, Xuejiao J Gao, Yuxin Wan, Xiyun Yan, Wei Jiang, Bing Jiang
Zitieren
APA
Xue, B., Wang, S., Wu, T., Wang, L., Gao, X. J., Cao, M., Tang, M., Wan, Y., Yan, X., Jiang, W., & Jiang, B. (2025). Nanozyme eye drops for retinal barrier penetration and vasculopathy repair. Science Advances, 11(38). https://doi.org/10.1126/sciadv.adu5571
Vancouver
Xue B, Wang S, Wu T, Wang L, Gao XJ, Cao M, et al. Nanozyme eye drops for retinal barrier penetration and vasculopathy repair. Science Advances. 2025;11(38). doi:10.1126/sciadv.adu5571
BibTeX
@article{Xue2025,
author = {Xue, Bai and Wang, Shuyu and Wu, Tingting and Wang, Lulu and Gao, Xuejiao J and Cao, Mengyuan and Tang, Ming and Wan, Yuxin and Yan, Xiyun and Jiang, Wei and Jiang, Bing},
title = {Nanozyme eye drops for retinal barrier penetration and vasculopathy repair},
journal = {Science Advances},
year = {2025},
volume = {11},
number = {38},
doi = {10.1126/sciadv.adu5571}
}
EUVIMED